Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
It is easy to make as big a volume as desired for a hedge, MM, etc. Just put shares from one account to another, for example.
Congratulations on those who have averaged down and held on so far, but Chris, seriously do you truly believe weyl will be bought out at a reasonably good price, at today's deteriorating tech environment due to Donald Trump's personal hatred of big high-tech companies, and on-going widespread global antitrust investigations against US big tech companies.
If no one was interested in buying weyl in the past, no one would be interested in buying weyl today, if any, at a reasonably good price.
So I guess, as your message board friend, I think it's time to get lightening some and get some cash and put that cash somewhere or in the bank.
I suspect the recent runup is just a setup or a ploy but how long the funds behind it will support is a big question.
The runup could continue or it could stop suddenly and back down. I have seen too many occasions like this before.
Just my comment, and think you totally deserve this runup, and hope you are well and prosperous.
By now longs should understand the importance of legally allowed non-transparency to the manipulated stock price of nwbo.
Linda shall have all the rights and flexibility to keep to herself the important news and timeline, and to release the news at the time she deems appropriate.
Because I have full confidence in her to get DCVax-L commercially available to patients who need, followed by DCVax-D, I forgo my desire for timely news within a period of six months.
I strongly believe she will deliver the most important news within that period, and it may come much earlier than we have expected.
The so-called and called-for transparency in the specific case of nwbo is no good for longs, but day traders, swing traders, and of course the naked short wolfpack.
Lock your shares, buy low, and wait patiently for the big news!
I rarely respond to posters like you who have said they have had no position despite posting endlessly 24/7 for year in this board, but I am sometimes no so strictly disciplined.
Linda Liau said in essence regarding those 100 patients who have lived over three years that "the majority of them not only live long term but also live progression free." [these are unprecedented, never seen in other trials!]
Based on the blinded data and subsequent update, it indicates it is highly likely that about 20% of all the patient population in the trial have lived and will live over 5 years.
Patients experience flu like symptom after injection of DCVax-L or placebo. Investigators will be quite sure how things are going from MRIs, blood analyses regarding possible immunogenicity activities of patients due to, oh, not placebo plus stand of care, but DCVax-L.
Adequately more data and evidence strongly indicate DCVax-L is safe and efficacious.
So chew the information, slowly and conscientiously, for I don't want your reply.
And please come to this board and let me know what's the result of your chewing after topline data is released, which I believe may come in August the earliest, and Nov the latest.
Not many people realize or remember a good phase 1/1b results with a lucrative market potential are usually worthy of a several hundred million market cap.
Well, we have DCVax-D which shows such a potential with excellent data. A new publication which is about to release may pleasantly wow the market.
And yet we are now sitting at a market cap of less than two hundred millions.
For the time being though more importantly we have DCVax-L which from any read and angle shows it is better than anything ever existing in treating GBM, the most deadly and the most difficult to treat cancer. I know it is still uncertain until it is certain by topline results, but
We are at a couple of hundred million market cap? Unbelievable!
When people disappointed from self-imposed unrealistic expectation on ASCO, duped and fermented by the wolfpack, swing traders and the like posed as lawyers, scholars, or other innocent investors, when people were stunned by a few pennies of price drop like chickens in a major storm, my fingers were working tirelessly on the keyboard, hitting buy button at price in the range of around $0.25.
Simply put, why anyone would bother by a few pennies of swing or even a few dimes of swing, since only a genius with a lot of luck can predict such a movement once or twice, if nwbo is worthy of several dollars or several tens of dollars per share when all dusts settle.
Always have some dry power in case a buying opportunity comes!
Why I have kept buying?
One of the reasons, in addition to the favorable prices thanks to the collected effort of the worlfpack, swing traders, and a few genuinely disappointed longs who embarked on panic selling, is that I believe a partnership deal is in the making as the company is putting a final touch in its draft SAP, to be submitted shortly.
After taking into account the comments, and feedback from RAs, the draft SAP will be quickly finalized, which may or may not need to submit to RAs again, if the company feels reasonably comfortable with it, meaning all major issues in the SAP are agreed upon by RAs. So a timeline from a couple of month to a few months at the most should be enough for this part of the work.
The rest of the work should be quite easy: at this time all outstanding queries should be all resolved; the company should be able to lock data and its statisticians should be able to analyze the data in a day or two.
After all, what is the most important is to make outmost effort to make the SAP a success, and in return it will guarantee that the data are correctly, efficiently and optimally interpreted. So it's no big deal for me to be able to see the data in a couple of month or in one half of a year.
Obviously, the existence with an increased solid footing of the company has been known by now, aided by blinded publication, presentations/lectures of Dr. Linda Liau, and of course the big booths in ASCOs and the accompanying presentations since years earlier.
I think when Northwest Bio cleared its booking with Cognate a short time ago, it is a harbinger for what it is coming for me, and it is certainly the interests of big pharmas to come onboard sooner than later after all the information has been made public so far regarding company's DCVax platform, as well as the failed trials by big pharmas in regards to GBM. It seems Northwest Bio is the only company standing today in fighting GBM!
Imagine Merck signs a partnership deal with nwbo with an upfront payment of several tens of millions, and several milestone payments of a total of billions on events of SAP finalization, positive topline data, BLA submission, FDA approval, etc., for an undisclosed percent of rights of the DCVax platform, including development of DCVax-D. In that case, what will be the reaction of the market, which has been infested by senseless and endless negativities toward the company?
BTW, Linda has my full support for ignoring all the noise. Pedal to the metal!
[why not a year earlier to do SAP, well it could not incoporate all we known to day's data]
Bought more around $0.252, want to buy more when all settle down and price stabilizes, either around 0.26 or 0.31
Nothing unexpected of yesterday's presentation, yes maybe a bit of disappointed if one expects substantial news. No blame to Linda because she has not hinted otherwise, and instead she did hint anyone should not expect too much as she dropped from presentation list.
Fundamentally, progresses have been made: SAP near completion, data scrubbing almost done, and indeed both progress in parallel.
Linda must understand the rule of publicity and market sentiment: under-promise and over-delivery.
After all, this is a binary stock. Only way to play it is buy low and sell on news (big news or FDA approval, or when nwbo becomes big pharm!)
It will slowly come up above 0.3 barring no news. What the big difference if we reach $5 today and September. I say some but not much.
CDEL plays solo today, painting the floor as its will. Buying, including mine not enough to make it collapse.
Need volume!
For those people who are here for a long-term ride up starting next week after this freaking long Memorial long weekend, rewarding days, months and years are ahead.
We must forget the long testing past and be focused on what good will come in days, months, and years ahead, starting from a reverse of news, followed by topline, multiple new trials for new indications, commercial success ...
For those who are here day trading or penny swinging, good luck to you too if you didn't change your mood every time there is a penny change in price, and if you don't spew nonsense in mb;
For those who are shorting, you are damned.
AS essential (not nominal) float is tightening, and it will be further tightening or even locked up, there is a new dynamics in the working, and of course
THERE WILL BE NO CHEAP SHARES!
Today the Real-Time Level 2 Quote of OTC Market/NWBO is not working, a rare occasion as I have watched it almost daily:
https://www.otcmarkets.com/stock/NWBO/quote
People should have all known when we talk about the wolfpack, or evil short, we refer it to naked short, despite "the innocent" citation of the legal or registered short interests cited by those posters who are definitely the ones may well be involved in the naked short. Strange? Absolutely No.
One should understand this even if there are no separations between the main groups of patients in the trial, as long as the trial shows a long and thick tail as we know from unblinded data release, trust me the company via brilliant intelligent UCLA Dr. Liau's team will be able to prove it is DCVax-L that chiefly contributes to that long and thick tail, via various medical and analysis tools and immune data.
One also should have understand now if DCVax-L is approved by FDA alone, a market cap of at least $5 billion should be readily reached in short period of time, which is equivalent to about $5 ~ 6 per share on fully dilute base, excluding other indications, and DCVax-D, although in reality, I expect much more than that.
THERE WILL BE NO CHEAP SHARES, LET ALONE CHEAPER SHARES!
[When positive data are announced, the overwhelming majority of shares will be locked up, and shorts will forever remember that moment of hell they well deserve.]
Actually one of the fundamental reasons for naked short, instead of illegal short, is the relative abundance of shares available for borrowing.
The widely available shares which can be borrowed encourage naked short because it diminishes the fear of the outright disaster, namely, there will be no shares to buy to cover even at an unbearably high price.
So the common practice is to naked short "a perceived weak company" for utmost gain (bankrupt the company") via naked short only if there are readily available shares which can be borrowed.
As float is tightening and the previously readily available shares diminish, it then discourage the naked short for the same reason, that is the fear for unable to cover now becomes a reality.
Which I think we are now experiencing as the float of nwbo is tightening, and it will be basically locked up if the company releases successful trial data after an initial sell for profit.
That's also one of the reasons, the wolfpack (ie, the naked short force) would like you to lock profit immediately when share price surges by following a pattern of selling 1/3 or 1/2 at least, disregard of what being a potential achievable market cap.
If price rises to $1, roughly equal to $1 billion market cap, would you sell; $2, $2 billion dollar market cap, would you sell ...
The wolfpack would like you to sell regardless..
That's why I pretty much enjoy this silence, thanks Linda!
AS we are awaiting for topline data, the radio silence is the best friends of longs and the worst enemy of the wolfpack.
THERE WILL BE NO CHEAP SHARES, LET ALONE CHEAPER SHARES!
Very interesting two sets of information taken from
Publish Date Title Period End Date Status
05/16/2019 OTCQB Certification - OTCQB Certification
12/31/2018 A
07/02/2018 OTCQB Certification - OTCQB Certification
12/31/2017 A
which indicates Public Float reduced from 425,943,839 as of 6-30-18 to 348,376,281 as of May 9, 2019 by 77,567,558 shares while outstanding shares increased to about 544,469,782 shares.
As outstanding shares increases, significantly more shares have been pulled out of free public trading. In the meantime, from the two sets of filing (I quoted below in quotation marked) it also shows the Number of Beneficial Owners holding at least 100 shares has drastically reduced, and that may at least partially explain why we have had significantly increased whining posters posting as long aiming for cheap shares.
"d.Please provide the following information as of the latest practicable date:
i. Number of Beneficial Owners holding at least 100 shares:118 as of April 30, 2019 (“Beneficial Owner” shall mean any person who, directly or indirectly has or shares voting power of such security or investment power, which includes the power to dispose, or to direct the disposition of, such security.)
ii. Number of shares in the Public Float: 348,376,281 as of May 9, 2019
(“Public Float” shall mean the total number of unrestricted shares not held directly or indirectly by an officer, director, any person who is the beneficial owner of more than 10 percent of the total shares outstanding, or any Affiliates thereof, or any Immediate Family Members of officers, directors and control persons.)
https://backend.otcmarkets.com/otcapi/company/financial-report/220637/content
[As of May 2019: all senior officers and directors of the company hold about 196,093,501 shares, which when added to public float equals to 544,469,782 shares]
and
"d.Please provide the following information as of the latest practicable date:
i. Number of Beneficial Owners holding at least 100 shares:12,142 as of 6-30-18 (“Beneficial Owner” shall mean any person who, directly or indirectly has or shares voting power of such security or investment power, which includes the power to dispose, or to direct the disposition of, such security.)
ii. Number of shares in the Public Float: 425,943,839 as of 6-30-18
(“Public Float” shall mean the total number of unrestricted shares not held directly or indirectly by an officer, director, any person who is the beneficial owner of more than 10 percent of the total shares outstanding, or any Affiliates thereof, or any Immediate Family Members of officers, directors and control persons."
https://backend.otcmarkets.com/otcapi/company/financial-report/196848/content
Very interesting two sets of information taken from
Publish Date Title Period End Date Status
05/16/2019 OTCQB Certification - OTCQB Certification 12/31/2018 A
07/02/2018 OTCQB Certification - OTCQB Certification 12/31/2017 A
which indicates Public Float reduced from 425,943,839 as of 6-30-18 to 348,376,281 as of May 9, 2019 by 77,567,558 shares while outstanding shares increased to about 544,469,782 shares.
As outstanding shares increases, significantly more shares have been pulled out of free public trading. In the meantime, from the two sets of filing (I quoted below in quotation marked) it also shows the Number of Beneficial Owners holding at least 100 shares has drastically reduced, and that may at least partially explain why we have had significantly increased whining posters posting as long aiming for cheap shares.
"d.Please provide the following information as of the latest practicable date:
i. Number of Beneficial Owners holding at least 100 shares:118 as of April 30, 2019 (“Beneficial Owner” shall mean any person who, directly or indirectly has or shares voting power of such security or investment power, which includes the power to dispose, or to direct the disposition of, such security.)
ii. Number of shares in the Public Float: 348,376,281 as of May 9, 2019
(“Public Float” shall mean the total number of unrestricted shares not held directly or indirectly by an officer, director, any person who is the beneficial owner of more than 10 percent of the total shares outstanding, or any Affiliates thereof, or any Immediate Family Members of officers, directors and control persons.)
https://backend.otcmarkets.com/otcapi/company/financial-report/220637/content
[As of May 2019: all senior officers and directors of the company hold about 196,093,501 shares, which when added to public float equals to 544,469,782 shares]
and
"d.Please provide the following information as of the latest practicable date:
i. Number of Beneficial Owners holding at least 100 shares:12,142 as of 6-30-18 (“Beneficial Owner” shall mean any person who, directly or indirectly has or shares voting power of such security or investment power, which includes the power to dispose, or to direct the disposition of, such security.)
ii. Number of shares in the Public Float: 425,943,839 as of 6-30-18
(“Public Float” shall mean the total number of unrestricted shares not held directly or indirectly by an officer, director, any person who is the beneficial owner of more than 10 percent of the total shares outstanding, or any Affiliates thereof, or any Immediate Family Members of officers, directors and control persons."
https://backend.otcmarkets.com/otcapi/company/financial-report/196848/content
MRNA versus NWBO (not a competition in any way) in terms of market cap:
MRNA's almost 8 billion market cap is a mirror how market is corrupted or working. Yes its pipelines are promising as of yet despite all in early phase I trials and it may embark on a phase 2 trial soon pending FDA approval. Remember too many biotech companies with early promising products in early trials have faded away unnoticed, and it's difficult or lucky to be able to move such products into phase 3 trial.
I have seen and experienced too many such companies (half long and half short in my investment), and now I almost don't invest in any company without a phase 3.
With the support of both big Pharms and the Wall Street money, MRNA can maintain a market cap of around 8 billion despite its very early in the game of the company.
On the other hand, NWBO, now in the cusp of Phase 3 data revelation and commercialization, has capped around 150 million ~ 200 million by the market (yes we are all familiar with this story and its implications of NWBO's platform so no more details to be repeated here).
The contrast is unbelievably startling and absurdly insulting!
The truth is when conception changes, everything will and has to change with justifiable market cap.
[Anybody still think we will only be trading with a market cap of 1 or 2 billion when we have successful trial data? SORRY, THERE WILL BE NO CHEAP SHARES.]
NWBO share price will rise big time while the market will be down big time today as Trump escalates trade war with China by threatening increase of tariff from 10% to 25% Friday, and potentially of more Chinese goods.
There will be more liquidity today capitulated from the market of which some gets to move in our way.
That's a pattern observed before, and it should be more true as we freshly heard LL's words re PF long-term survival and in anticipation of ASCO revelation.
Enjoy!
The excitement is built up rightfully around the recent LL's video, regarding her statement re those top 100 patients who have lived roughly three years plus, of whom the majority have also lived progression free.
It is significant because it strongly indicates DCVax-L vaccine has indeed done its job what it is designed and intended to -- its Mechanism of Cction (MOA) is confirmed, by prolonging patients PFS living and then hopefully OS as well.
And it can only be done by mobilizing killer cells to attack residual cancer cells after vaccine administration, and mobilizing killer cells whenever new cancer cells are reborn, and launch attacks on these newly generated cancer cells due to memory. As a result, it can prolong both PFS and OS of patients who have received the vaccine.
And it is important that the results are absolutely not by a chance, because the existing of such a significant proportion of PFS patients has not been seen for those patients who have received the current standard of care or those from Optune trials.
Indeed, as many have readily pointed out it also busts the long persistent short theory of trial failure at a perceived interim analysis.
Of course, the trial needs to be unblinded to have a definite conclusion.
[Just realize this post is not specific to your post antihama]
The video's appearance in Youtube coincided with share price appreciation from $0.27 to $0.3 with a relatively substantial volume increase in the range of 3 million.
Face it Ladies and Gentlemen: Everybody in this board or the like who posts, either endlessly 24/7 for years or occasionally, or who comes and goes all the time, is aiming at cheap shares either directly or indirectly (those who do so by heeding to the work orders of their funds so they may not be direct shareholders of this wonderful company and who can readily claim to have no shares at all despite posting tirelessly, either part of the wolfpack or not).
The problem or truth is the greed, which on one hand prevents an ordinary retail investor from seeing the forest for the trees despite being surrounded by cheap shares. In this regard, those without shares but posting tirelessly have accomplished their work preventing the share price from having higher pressure to rise; it's the same problem of the greed, which also prevents the funds from taking initial and/or substantial positions before everything is crystal clear by pivotal data despite their tireless efforts preparing the market to the eventuality of a successful trial. When the time comes, they may still debate the results hoping that the market cannot distinguish between days and nights, so they may still argue the share price can only rise to such a level such as $1 or 2$ even if the market having a stellar data in its face because the price simply cannot jump too high from a relative low level such as $0.3 or $0.5. What a faulty logic!
The utmost purpose is of course cheap shares. When they work hard to warn the market, they will be busy accumulating the cheap shares by their definitions. With some undeniable data, they may also forget the market may be manipulated in some conditions but it cannot be in other conditions and forever.
So the chance is that they will be overwhelmed by a tide wave of huge share price normalization supported by the general market. As to how high the share price can rise, the best reference is clearly the market cap of other similar companies, and such examples are plenty, anywhere in the range from around $5 billion to $20 billion.
Yes, we may not be able to take over a market cap of $10 billion (roughly equal to $10 ~ $15 per share on fully diluted base) for example right away or within a short period of time after undeniable data are released, but to say $1 or $2 is the ceiling on such occasion is utterly absurd, but if the reality is otherwise, then get dry powder ready, and there is not other way to do it: get in big!
Too many people are hoping to get in cheap without taking any due risks, and for that something is definitely not right!
Are the two still blinded data sets released still not enough to de-risk? Then I would say it's the greed and a dumb greed that has blinded you!
BTW, I still expect a huge short squeeze is in the working!
It seems it is the first time presentation will be given by two relevant persons of the company at the same time and same avenue on Update of DCVax.
But update on which presentation or data set or upcoming topline before 2 June, and on which vaccine, L or D or both?
Unlike many here, I like this ambiguity as we approach destination, and I give Linda the full flexibility to get things right.
I am happy on all things have been going since property sale, and if we can get rid of those who repeat nonsense or FUD, I will be happier.
But happy is enough for me, particularly I have dry power ready.
Pedal to the metal!
Hated to see but it happened after that ominous 911 shares took down last Thursday.
Prepared with fund ready, and bought 30K shares just in the last ten minutes.
May buy more sometimes later today.
Have seen this too many times.
See that CDEL bit at 0.2559 but ask for 0.26?
Those pigs play game in Easter Monday. Holy shits. They must be true terrorists, but they will be defeeated!
I concur Bashin Street Blues' opinion. The point is as I said it before on the day it happened: the whole twist was not just an innocent accident but strongly suspicious.
Of course "it was a clerical error" or something if happens once but for the second time -- maybe not (particularly it happened just the next day we had encouraging interview featuring Dr. Linda Liau), and if it happens the third time (not yet, but be prepared) for any lame excuse?
David Innes and/or Black shall watch it closely, and find a way to prevent it from happening again. It is not just the trading platform, it can happen anywhere related to nwbo. For instance, the message boards may be suddenly unavailable due to "maintenance" or other lame excuse (I remembered it happened before) when news was out or rumor was flying high, etc., or the company's website may not be accessible as well...
It is a war against the wolfpack, and anyone particularly the company executives have to be beware, alert and prepared.
With regard to stock price, it seems the wolfpack would like it to be traded below $0.3 as their redline for obvious reason, so as to prevent the company from getting warrant exercised money, etc. unless there is substantial news.
Pity Linda doen't have a powerful person who can commit significant resources to fight (buying stock at this low price). Has she divorced from her rich husband?
So David Innes better find some powerful believers of this company. This company trades at $0.3 is an insult to whom who have performed their DD.
Linda and his husband or their friends are just peanut, let alone Bigger Capital. For God sake, they even don't have the resources to buy all shares available at pity $0.3.
In recent days, a wolf is hiding before the crowd:
MPID Ask Price Size Time
CSTI 0.29 259,514 10:42
CSTI can always come up with endless cheap shares, and yet Bigger Capital and Linda's friends can do nothing with it. Pathetic!
Ironically and fortunately, this company has the support of lots of diehard retail investors, me included
I have bought every week despite I had told my wife I was done a long time ago.
And why not at those low prices?
It's sunny day ladies and gentlemen. We have entered the fifth months of the process of concluding the trial.
As of today at least, we can conservatively say finalizing SAP "is well underway," perhaps on its way back to Linda's desk, perhaps it is already sitting in the tray of her fax machine since she was out yesterday to do that "useless" conference presentation; and
Of course to be able to finalizing SAP, PFS adjudication must have successfully concluded; thus I say smiley Linda Liau showed up in Spectrum News interview with that gigantic pair of syringes printed DCVax-L.
So what else we ought to know or expect: I can confidently say in the near future the company will be able to do data freeze and unblinding the trial. They may elect not to say anything until
either topline or something up to your imagination.
I am in the mood of seriously considering adding more to my position.
GLTA!
**CANCELLED** Seminar with National Cancer Institute director Dr. Norman Sharpless
**CANCELLED** This seminar has been cancelled due to Dr. Sharpless taking on a new role at the U.S. Food & Drug Administration.
https://cancer.ucla.edu/Home/Components/Calendar/Event/2358/130
Hi tryn2, sorry for this late reply.
From the public-known information, it is no way anyone can draw a definite conclusion on how many naked short shares are there. Nonetheless, the company via Les has repeatedly told some investors that there has been a widespread naked short campaign raised against the company. It is no reason for me to totally discount his claim as he certainly has more information in that regard than anyone outside the company inner circle.
Moreover, the pattern of trading over the years has strongly pointed to that reality. At this period of time when share price has been beaten so badly from over $12 to the range of one and two dimes or so, if the short really want to make more money if they have covered they should have hyped the price instead, or at least let the price go of the freedom up to the market so that they can short heavily again knowing the company is an eventual bust. That is how it usually happens when a company approaches a binary event while its share is trading low. But the fact is absolutely opposite:
The short have never given up, and instead have seemed to intensify their efforts. Particularly whenever there is or there is an anticipation of a new positive information there will always be a coordinated campaign to damp the hope and the enthusiasm via renewed FUD in message boards, mysterious change of trading status of the company shares (remember the pink sheet twists), suddenly brazened sell of stock, etc. and if the enthusiasm or appetite for shares are high, they would usually wait for a while, and the price would almost all the times come off the high, and once again trade in a narrow range. Any FUD and brazen accusation always comes with some coordinated selling, a selling of no reason at all.
So I believe besides the legally traded short shares of around 11 million, there are at least multiple that numbers of shares sold naked. As a result, I do believe there will be a monstrous scale short squeeze if Les' numbers are correct or at least a major short squeeze if my conservative estimated numbers are correct.
GL
The trading pattern yesterday and today strongly suggests manipulation, and maybe a coordinated manipulation: after a weekend when potential investors just had an encourage read/watch/listen of a video clip featuring Dr. Linda Liau in Spectrum News 1, you found out early Monday morning nwbo for whatever reason became a pink sheet company -- that bright pink hurts really.
Then, trading volume was thin, very thin, while potential investors were scared away.
Again today, almost whenever you bought the next thing you saw was the price drop a little bit below what you had just bought. For example, if someone was willing to buy at 0.297, what was the reason to ask 0.296 if you want to sell?
These patterns are not a fit to hedge but pure manipulation. Actually, anytime I saw this I could not help but buy more knowing that when time comes the share price will appreciate exponentially more than it should be due to short squeeze.
I believe a monstrous short squeeze is coming soon.
Regulatory supervision and justice for small biotech companies -- don't hold your breaths for it -- SEC's exists for market stability, meaning to protect big companies, including bad players.
In the case of nwbo, Mr. Black serves as deterrent, nothing more or less; if the trial is a success, market will take care of itself at least within a period of time; unless there are substantial evidences collected and submitted to SEC or the court, there would be very difficult for due recourse.
I don't think yesterday's bizarre recurrence of wrong designation of nwbo as pink is not coincidental or accidental (I also asked for someone here to contact Innes while I myself had contacted OTC Market and the company). Be prepared for future "blackout" of even message boards, and general and specific misinformation as we approach the inflection point.
Most people may have not realized the true beauty of DCVax platform is not that we can see a successful DCVax-L trial in GBM indication, in a way of statistical significance in survival and PFS, or indisputable survival long tail over historicals and concurrent results, but that the concept or the mechanism of action of the platform can be proved.
As a result, the platform will work on other indications, and the process to get regulatory approvals for other many indications will be expedited or very short.
Has to run, GL [not intended to reply to photonic5's specific post, sorry]
Urgent: can any of you who have David Innes' email notifies him the wrong designation of nwbo as pink in the link:
https://www.otcmarkets.com/stock/NWBO/disclosure
It has happened before, and I don't think it is accident. There are always someones sneaky and filthy in this world.
Thanks
Yes, Flipper whenever you think about it, it's hard not to get emotional, but look at the wolfpack who also have lovely ones around who suffer from cancers from time to time.
Yet, how could a person short a stock like this, despite having tons of opportunities to get out fatty rich if sold, still hang on relentlessly on a stock costing two and three dimes a share?
How on earth can these people clearly and handsomely separate their greed and the human emotion?
Maybe they don't have any human emotion, and they are immune to human guilt.
BTW, David Innes' main responsibility is to talk to potential investors!
Cancer 'vaccine' shows promise in human trial of lymphoma patients
An experimental cancer vaccine showed promise in a small clinical trial, according to a study in Nature Medicine.
Mount Sinai tested the treatment in 11 patients with lymphoma.
The vaccine is used in people who already have cancer. It's not preventive like the flu shot.
Angelica LaVito | @angelicalavito
Published 2 Mins Ago CNBC.com
https://www.cnbc.com/2019/04/08/cancer-vaccine-shows-promise-in-human-trial-of-lymphoma-patients.html
"The vaccine activates dendritic cells, which are responsible for initiating immune responses. These cells then instruct T-cells to attack tumors in a person's body, like generals instructing soldiers how to fight."
Our DCVax D is better than this; it seems more and more cancer vaccines based on DC are coming to light
It's good that it seems everyone has forgot Linda's upcoming presentation at World's Vaccine Congress on 16 April at 12:40pm and the seminar in UCLA cancer center with new FDA chief one day later on 17 April.
It's better to expect nothing new than sorry, but anyhow, I still continued buying shares yesterday and today.
I think SAP has been finalized or concluded and submitted to RAs; the company may elect not to announce it publicly when it receives the approvals from RAs so the next big news may just be topline.
Shorts have some time to play before topline, and if the data is undeniable shorts may have a few hours (like the case of dndn when positive data was announced) or a day to deceive.
Not like some who have thought that shorts have the power to cap the rise of price in case of positive data, but they don't.
Fliper44, I think you have over read and over analyzed what Marzan has conveyed of his conversation with Dr.B
My interpretation on what Dr.B said to Marzan is that of course so many patients have lived so long because of 1) the obvious reason as you stated in your post, and 2) even those patients who have seen their progression less than 25% of their original sizes may have had extended overall survival due to DCVax-L (note the word, "even")
Even what my interpretation is true to Dr. B's statement or what he was intended to say, what he has said is still his opinion or speculation at this stage, which is still all based on blinded data.
It's surprising to me by now he has not been in your ignore list yet, along with other those familiar ones with no stakes and yet posting 24/7 for years.
All know, including the wolfpack, it all depends on data. I don't know how good the data will be.
But we will know soon.
Jerry Mah, Are you joking right? You have tagged to this little biotech company for years and have painstakingly reported to SEC anything you deemed negative or report worthy.
You have timely reported almost any company's sec filing at yahoo message board, IV and here in IHUB.
Yes, you are a perfect example for being a bystander.
Mr. Mah, keep on the good work because we need fuel when we take off.
Jerry, maybe someday we should meet.
Lot of noise recently. Some family IDs resurfaced and some old ones still post 24/7 without taking a position, short or long.
Now this today the delayed 10k because of a variety of reasons including audit.
The audit of the book and practice, besides the obvious reason stated by the company, suggests the reason that is more important than the stated, that is for future uplifting nwbo back to Nasdaq or up to NYE.
Among various requirements, you need to have a clean audited book and practice according to the rules and regulations to be able to uplift.
In doing so, when the time comes, we will have a smoother and quicker uplifting.
Who have bought in today's hiccup? Apparently, not many people have got it. How many retail investors have David Innes talked to today?
There are always more important things to do, no exception for anyone.
Dave you need to talk to the Wall Street and don't read message boards too much!
The difference this time is that we are undeniably approaching some significant news, either it is SAP, data lock or even topline data announcement or major investment. Nobody should deny that since we have been 4 months after the company officially announced they were in the process of concluding the trial back in last Nov.
David should spend his time to talk to Wall Street not retail investors. I don't discourage him to not talk to retail investors, rather that he should spend most of his time talking to Wall Street.
Next time, when a retail investor is talking to him, can you please ask him whether he have talked to Baker Brothers, etc.?
Seriously, with the data we have had, ie, two interim blinded data, the chance of DCVax-L's success is probably very high. Even without separations between the two arms due to whatever causes, such as cross-over, or the like, I don't think it is very difficult for the company to show some concrete data indicating that DCVax-L is working according to its intended MOA. With its pristine safety profile, that would be enough for FDA to sign off the approval of DCVax-L for its intended use.
You need several big sharks coming into nwbo's water to scare away the shorts while injecting confidence to those kind of retail investors who post every day in message boards, or we have to wait for big announcement for permanent substantial share appreciation.
Not I care, because I have long determined not to sell a share before at least topline data, but it's just that it is tempting for me to buy more shares when I have had enough if the share price has not substantially appreciated.
Without big investment sharks, it's normal for share price wavers in either direction with not many volumes, since there are those low hanging warrants and not really convicted investors who hold them. Here I even let the wolfpack out of the equation.
So David Innes better use his time appropriately, and I expect big volume days are coming sooner than many would expected.
It's ignorant or disingenuous for anyone who brings DNDN's Provenge as a case for caution over FDA's approval decision in regard to PFS.
Simply put, if DNDN were faced with FDA decision today with its first phase III trial results, Provenge would be easily approved, unlike in the actuality about 10 years ago that it was refused for approval and the company was asked to have second P3 trial as confirmation for OS.
How come? Provenge at that time was surrounded with safety concern as a first cancer treatment vaccine ever put on FDA's table for decision in history so the concern over its safety might be genuine, but it was outrageously exacerbated by shorts.
So with safety concern and a slightly efficacy, FDA at that time was reluctant to approval Provenge.
Today, if anything has been proven and it is even agreed by shorts is cancer treatment vaccines like DC based is safe, very safe.
So it's not comparable whatever even if there were not separations in term of PFS.
In today's knowledge and environment, FDA will approve DCVax-L in all cases below:
1) "Failed" PFS, but successful OS;
2) Successful PFS, but "failed" OS;
3) a thick long tail alone;
4) Both successful PFS and OS;
others?
UCLA Seminar with National Cancer Institute director Dr. Norman Sharpless, the newly appointed acting chief of FDA
Talk title TBA
Date: April 17, 2019 12:00 PM - 1:00 PM
Location: NRB Auditorium
Los Angeles, California 90095
https://cancer.ucla.edu/Home/Components/Calendar/Event/2358/1195
oin us in welcoming Norman E. Sharpless, M.D., Director of the National Cancer Institute, to the UCLA Jonsson Comprehensive Cancer Center.
He will be participating in a ONE DAY ONLY VISIT to UCLA on Wednesday April 17, 2019. Dr. Sharpless will be presenting a seminar that is open to all UCLA staff, faculty and leadership.
Please be sure to save the date! More information to be forthcoming.
Date: Wednesday, April 17, 2019
Location: NRB Auditorium
Time: 12:00 p.m.
I have a simple principle guiding my investment in nwbo based on years non-stop data-based, and even-fud checked DD:
It's a buy when share price is blow $1, ie., the market cap is close to 1 billion on fully diluted base based on two progressively better interim data sets, ie., the data sets indicate a thick and long tail with yet-to-approved or unclear separations between various comparable groups.
The reason is that if the future topline data set were showing no separations, it's still highly likely it will show a thick and long tail, then the underlining vaccine will still be approved, though its approval may have to survive a battle of doubt waged mainly by bears, nwbo haters, nwbo's competitors, etc.
The good start point is DCVax-L's pristine safety profile. Assuming no separations, the thick and long tail will be undeniably a strong indication of efficacy; I believe the company will be able to show various data indicating that DCVax-L's intended Mechanism of Action is indeed at work such as killer cells infiltration, etc. With evidences for a working MOA and a thick and long tail even without clear separations due to cross over, any reasonable person will believe that the vaccine is working, so the final approval shall be no doubt in the card.
After approval, the market cap will move up to where it belongs, ie., at least several billions if not tens of billions.
The above is almost a worse scenario I can come up with at the time being, and I am a buyer.
But I have to make it clear that I do believe there will be separations between the various comparable groups based on what we have known in terms of SOC, other concurrent trials, our trials, etc, and I believe the price is outrageously low in this range.
Because of the long and repeated dilution history, and the never ending wolfpack attacks, we will experience numerous battlefields, like the one currently waged on around $0.3, which will be broken very quickly.
All in all, buy now and forget for a few month and you will be richly rewarded.
Actually Bill the impact on nwbo may just be positive considering how he was hired by Trump. Basically, he is comparably conservative than anyone at that time considered for the position by Trump. For example, the guy considered for the position before him is more liberal kind of guy who thought drugs/vaccines should be approved purely based on safety, meaning if it is safe, then they should be approved.
So I would think the chance of the new FDA boss who is more conservative than Scott Gottlieb is very low, and the chance of the new FDA boss who is more liberal than Scott is quite high.
Under Scott, DCVax-L with a long tail but no separation would be approved, so my sense is that we are better off after Scott's resigning.
One of the reason for his resigning is he has drawn the ire of tobacco companies, thus of some Republic politicians.
In general, his resigning may be considered a loss for big pharm for their future approvals of dangerous ICI, and Cart-t drugs/agents despite serious safety issues, but I don't see any impact on nwbo, if not positive.
I don't think there will be any direct impact at the time being. In a long run, it may all depend on who will be his successor.
Nonetheless if the data are as good as we think, particularly if there are obvious separations between early and late vaccined patients, and/or between early vaccined or total vaccined (including cross-overs) and those who have never received the vaccine in terms of HRs, nobody can deny the approval of DCVax-L for its intended use.
However, if the separations are not there or not very clear, but landmark survivals at 2, 3, 4 and 5 years are apparently better than historical survivals and/or NVCR's for example, then that may really depend on who will be FDA's new boss, and what are his/her opinions compared to Scott Gottlieb over drug/vaccine approvals for unmet medical needs.
Under Gottlieb, the above case of no apparent separations but with long tails will be approvable, imo.